Free Trial

Lantheus (LNTH) Competitors

Lantheus logo
$79.78 +0.97 (+1.23%)
As of 04:00 PM Eastern

LNTH vs. ONC, BNTX, SMMT, TEVA, ITCI, GMAB, RDY, MRNA, ASND, and VTRS

Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Beigene (ONC), BioNTech (BNTX), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Ascendis Pharma A/S (ASND), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

Lantheus vs.

Lantheus (NASDAQ:LNTH) and Beigene (NASDAQ:ONC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, community ranking, risk and analyst recommendations.

Lantheus has a net margin of 28.57% compared to Beigene's net margin of -25.94%. Lantheus' return on equity of 44.29% beat Beigene's return on equity.

Company Net Margins Return on Equity Return on Assets
Lantheus28.57% 44.29% 23.52%
Beigene -25.94%-25.12%-14.95%

Lantheus has higher earnings, but lower revenue than Beigene. Beigene is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantheus$1.54B3.48$326.66M$3.5222.20
Beigene$4.18B5.24-$881.71M-$3.72-59.52

Lantheus presently has a consensus target price of $132.67, suggesting a potential upside of 69.80%. Beigene has a consensus target price of $319.00, suggesting a potential upside of 44.07%. Given Lantheus' higher probable upside, equities research analysts plainly believe Lantheus is more favorable than Beigene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Beigene
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

99.1% of Lantheus shares are held by institutional investors. Comparatively, 48.5% of Beigene shares are held by institutional investors. 1.5% of Lantheus shares are held by insiders. Comparatively, 6.6% of Beigene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lantheus received 333 more outperform votes than Beigene when rated by MarketBeat users. However, 78.57% of users gave Beigene an outperform vote while only 66.15% of users gave Lantheus an outperform vote.

CompanyUnderperformOutperform
LantheusOutperform Votes
344
66.15%
Underperform Votes
176
33.85%
BeigeneOutperform Votes
11
78.57%
Underperform Votes
3
21.43%

In the previous week, Beigene had 4 more articles in the media than Lantheus. MarketBeat recorded 21 mentions for Beigene and 17 mentions for Lantheus. Lantheus' average media sentiment score of 0.56 beat Beigene's score of 0.29 indicating that Lantheus is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lantheus
11 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Beigene
2 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Lantheus has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Beigene has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Summary

Lantheus beats Beigene on 10 of the 16 factors compared between the two stocks.

Get Lantheus News Delivered to You Automatically

Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LNTH vs. The Competition

MetricLantheusDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$5.35B$2.62B$5.19B$8.42B
Dividend YieldN/A0.71%4.99%4.16%
P/E Ratio12.997.5726.4119.67
Price / Sales3.48338.74388.54119.76
Price / Cash11.9815.7538.3134.62
Price / Book6.565.496.634.48
Net Income$326.66M-$65.73M$3.22B$247.85M
7 Day Performance-2.53%-2.03%1.04%3.54%
1 Month Performance-23.98%-2.89%6.37%11.12%
1 Year Performance-1.85%-20.73%12.77%5.33%

Lantheus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LNTH
Lantheus
4.4274 of 5 stars
$79.78
+1.2%
$132.67
+66.3%
+0.1%$5.46B$1.54B13.27700
ONC
Beigene
3.0894 of 5 stars
$254.16
-0.6%
$318.88
+25.5%
N/A$25.14B$3.81B-30.849,000Analyst Revision
BNTX
BioNTech
2.6353 of 5 stars
$101.10
-3.7%
$143.44
+41.9%
-0.2%$24.26B$2.75B-48.143,080Analyst Forecast
Positive News
SMMT
Summit Therapeutics
2.968 of 5 stars
$28.02
+0.4%
$37.40
+33.5%
+385.6%$20.67B$700,000.00-100.07110Analyst Upgrade
Positive News
TEVA
Teva Pharmaceutical Industries
3.5021 of 5 stars
$16.40
+1.3%
$23.43
+42.9%
-2.3%$18.59B$16.54B-11.3136,800Analyst Upgrade
News Coverage
ITCI
Intra-Cellular Therapies
0.6177 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560Analyst Forecast
News Coverage
GMAB
Genmab A/S
3.3707 of 5 stars
$21.55
+0.3%
$39.17
+81.7%
-35.4%$13.82B$21.53B12.391,660Earnings Report
Analyst Revision
RDY
Dr. Reddy's Laboratories
1.7011 of 5 stars
$13.88
-0.9%
$17.00
+22.5%
+1.6%$11.58B$311.31B22.0924,800Earnings Report
News Coverage
Positive News
MRNA
Moderna
4.539 of 5 stars
$27.84
+0.8%
$53.95
+93.8%
-81.3%$10.76B$3.14B-3.003,900
ASND
Ascendis Pharma A/S
3.3739 of 5 stars
$170.74
-0.8%
$216.07
+26.5%
+25.9%$10.41B$363.64M-24.05640Analyst Forecast
VTRS
Viatris
2.131 of 5 stars
$8.59
-0.7%
$10.50
+22.2%
-24.4%$10.19B$14.74B-11.6137,000Earnings Report
Insider Trade

Related Companies and Tools


This page (NASDAQ:LNTH) was last updated on 5/15/2025 by MarketBeat.com Staff
From Our Partners